An Indispensable Partner

To fulfill the promise of on-target gene editing from discovery to patient

[ Company Overview ]

Physicians and regulators are concerned that changes to a patient’s genome might have unintended, life-altering consequences

It will be imperative to understand the off-target risk profile of your therapy to inform regulatory filings, support patient and clinician decision making, and to conduct post market surveillance

Invaluable gene editing off-target insights from initial research to patient therapies

Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.

Discovery features
Development features
Commercialization features

SeQure Dx comprehensively evaluates and confirms on- and off-target events using proprietary analytical tools that deliver unparalleled sensitivity and scalability.

Our diagnostics are editor-agnostic and scalable — providing both individual and population level insight.

Join the team – help us make safe gene editing a reality

Come join an energetic, focused, and dynamic team that supports career growth as well as personal well-being.

  • SeQure Dx to present at American Society of Gene and Cell Therapy (ASGCT) on the importance of incorporating population heterogeneity evaluation into gene editing and cell therapy off-target analyses

    Full Release ❯

  • SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients

    Building on Dr. J. Keith Joung’s ONE-seq platform, SeQure Dx has developed a portfolio of assays and data solutions to find, assess, and manage off-target risks from discovery to clinical development to patient impact.Full Release ❯